신기능 저하와 골다공증 위험 인자가 있는 환자에서는 tenofovir를 사용할 것이라면 TDF보다는 TAF를 선택합니다.
|
There are two formulations of tenofovir, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). For most patients, we recommend tenofovir alafenamide (25 mg daily) rather than tenofovir disoproxil fumarate (300 mg daily), if available. For those who were originally started on tenofovir disoproxil fumarate, we generally suggest switching to tenofovir alafenamide, particularly in older patients and those with risk factors for renal impairment or osteoporosis. Although there is more experience with tenofovir disoproxil fumarate compared with tenofovir alafenamide, tenofovir alafenamide appears to be equally effective and is associated with less renal and bone toxicity |
REF. UpToDate 2020.09.13
'소화기내과(간) > B형간염' 카테고리의 다른 글
| 급성 B형간염 진단, Acute hepatitis B, diagnosis (0) | 2020.11.23 |
|---|---|
| 임신부에서 만성B형 항바이러스제 사용, Antiviral agent in women who are pregnent (0) | 2020.09.13 |
| 신기능 저하 활동성 만성B형간염에서는 Tenofovir alafenamide (TAF)를 사용 (0) | 2020.09.13 |
| 만성 B형 간염 항바이러스 내성 치료 (2018 대한간학회 가이드라인, 2018 AASDL) (0) | 2020.02.23 |
| Interpretation of the hepatitis B serologic panel (2) False positive hepatitis B surface antigen (0) | 2019.11.24 |
